News Headlines

  1. IAVI, Minapharm, And ProBioGen Announce Memorandum Of Understanding To Progress Clinical Development, Manufacturing, Commercialization, And Access To Vaccines And Antibodies In Africa 10/10/2025

    IAVI, a nonprofit scientific research organization, based in New York, U.S.; Minapharm, the largest biosimilars manufacturer in Africa, based in Cairo, Egypt; and ProBioGen, a recognized leader in contract development and manufacturing, and a trusted technology provider based in Berlin, Germany today announced a strategic partnership to advance the end-to-end development and manufacturing of priority vaccines and biologics in Africa.

  2. RoosterBio And Secretome Therapeutics Announce Successful Completion Of Large Scale Bioreactor Production For Clinical Stage Cell Therapy Candidate STM-01 10/10/2025

    RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cells (MSCs), highly engineered media, and bioprocess development services, and Secretome Therapeutics, a clinic-stage company developing novel therapies derived from neonatal cardiac progenitor cells (nCPC) today announced completion of commercial scale production of Secretome’s lead nCPC, STM-01.

  3. BioSpring Enters Strategic Partnership With Luxna Biotech To Offer Manufacture Of Oligonucleotides With Luxna's Advanced XNA Amidites 10/9/2025

    BioSpring, a leading supplier of high-quality therapeutic oligonucleotides, today announced a new collaboration with Luxna Biotech Co., Ltd., a leading antisense oligonucleotides (ASO) company, enabling the manufacture of oligonucleotides incorporating Luxna’s proprietary Xeno Nucleic Acid (XNA) amidites, including AmNA, scpBNA, and 5′-CP.

  4. AstraZeneca Plans To Increase Investment And Scope Of Its Virginia Manufacturing Facility To $4.5B, Creating 3,600 New Jobs 10/9/2025

    AstraZeneca today announces that it will invest $4.5B in its new manufacturing facility in Virginia, a proposed increase of $500m to support the enhanced manufacturing capability of a broader range of medicines including cancer treatments.

  5. Bio-Thera Solutions Announces Expansion Of Partnership With Intas Pharmaceuticals For BAT2506, A Proposed Biosimilar Referencing Simponi® (golimumab), Through Exclusive Commercialization And License Agreement In Canada 10/9/2025

    Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, today announced an expansion of its partnership with Intas Pharmaceuticals for BAT2506, a proposed golimumab biosimilar, through an exclusive commercialization and license agreement for Canada.

  6. Chance Pharma Announces Commercialization Agreement With Huadong Medicine For Innovative Respiratory Drug CXG87 10/9/2025

    Chance Pharmaceuticals ("Chance" or "Chance Pharma"), a clinical-stage biotechnology company dedicated to the research and development of innovative inhalation therapies, today announced that it has reached an exclusive commercialization agreement with Huadong Medicine (Hangzhou) Co., Ltd., a wholly owned subsidiary of Huadong Medicine Co., Ltd. (000963.SZ, "Huadong Medicine"), to commercialize CXG87 in Mainland China.

  7. Samsung Biologics Introduces Optimized Manufacturing Framework, ExellenS™ 10/9/2025

    Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today unveiled ExellenS TM – an optimized manufacturing framework applied across the company's biomanufacturing network.

  8. Nasus Pharma Announces Expanded Agreement To Support Development And Commercialization Of NS002 Intranasal Epinephrine Program 10/8/2025

    Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced the execution of comprehensive agreements with Aptar France S.A.S. and AptarGroup, Inc. (collectively, “Aptar”), a leading global manufacturer of drug delivery systems, to support the ongoing clinical development and planned commercialization of NS002, Nasus Pharma's intranasal powder epinephrine product candidate.

  9. VectorBuilder Redefines Plasmid Standards With miniVec 10/8/2025

    VectorBuilder, a global leader in gene delivery technologies and CDMO services, today announced the publication of the miniVec plasmid system, engineered for safer, more efficient, and more scalable development of genetic medicines. The manuscript detailing this breakthrough is now available on BioRxiv.

  10. Sai Life Sciences, Agility Life Sciences, And Centrix Pharma Solutions Announce An 'Integrated CMC Partnership' To Accelerate Drug Development For Innovators 10/8/2025

    Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), Agility Life Sciences, and Centrix Pharma Solutions today announced the launch of an Integrated CMC Partnership designed to provide innovator biopharma companies with end-to-end Chemistry, Manufacturing and Controls (CMC) services.